Abstract
Disturbances of the basal ganglia processes is heavily involved in schizophrenia. Phosphodiesterase 10A (PDE10A) is a basal ganglia specific hydrolase, which plays an essential role in regulating cAMP/PKA and cGMP/PKG signalling cascades by controlling the magnitude, duration and cellular location of cAMP/cGMP elevation. Biochemical and behavioral data indicate that PDE10A inhibition activates cAMP/PKA signalling in the basal ganglia, leading to the potentiation of dopamine D1 receptor signalling, and concomitant inhibition of dopamine D2 receptor signalling. Preclinical evidence in a range of animal models suggests that a PDE10A inhibitor could provide efficacy on positive, cognitive and negative symptoms of schizophrenia and PDE10A inhibitors are currently being evaluated in clinical trials for the treatment of schizophrenia.
Keywords: Basal ganglia, Phosphodiesterase 10A, PDE10A, schizophrenia, psychosis, antipsychotic, cAMP/PKG, cGMP/PKG, signalling cascades, dopamine, pro-cognitive, striatopallidal, striatonigral, PDE10A structure
Current Pharmaceutical Design
Title: PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
Volume: 17 Issue: 2
Author(s): Jan Kehler and Jacob Nielsen
Affiliation:
Keywords: Basal ganglia, Phosphodiesterase 10A, PDE10A, schizophrenia, psychosis, antipsychotic, cAMP/PKG, cGMP/PKG, signalling cascades, dopamine, pro-cognitive, striatopallidal, striatonigral, PDE10A structure
Abstract: Disturbances of the basal ganglia processes is heavily involved in schizophrenia. Phosphodiesterase 10A (PDE10A) is a basal ganglia specific hydrolase, which plays an essential role in regulating cAMP/PKA and cGMP/PKG signalling cascades by controlling the magnitude, duration and cellular location of cAMP/cGMP elevation. Biochemical and behavioral data indicate that PDE10A inhibition activates cAMP/PKA signalling in the basal ganglia, leading to the potentiation of dopamine D1 receptor signalling, and concomitant inhibition of dopamine D2 receptor signalling. Preclinical evidence in a range of animal models suggests that a PDE10A inhibitor could provide efficacy on positive, cognitive and negative symptoms of schizophrenia and PDE10A inhibitors are currently being evaluated in clinical trials for the treatment of schizophrenia.
Export Options
About this article
Cite this article as:
Kehler Jan and Nielsen Jacob, PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia, Current Pharmaceutical Design 2011; 17 (2) . https://dx.doi.org/10.2174/138161211795049624
DOI https://dx.doi.org/10.2174/138161211795049624 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity
Current Medicinal Chemistry The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Future Targets for Immune Therapy in Colitis?
Endocrine, Metabolic & Immune Disorders - Drug Targets RNAi Screening for the Discovery of Novel Modulators of Human Disease
Current Pharmaceutical Biotechnology SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals Somatic Mosaicism in Cases with Small Supernumerary Marker Chromosomes
Current Genomics Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice
CNS & Neurological Disorders - Drug Targets Resistin and Oxidative Stress in Non-Diabetic Obstructive Sleep Apnea Patients with Nocturnal Hypertension
Current Respiratory Medicine Reviews Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target
Current Vascular Pharmacology Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research The Human Genome Puzzle — the Role of Copy Number Variation in Somatic Mosaicism
Current Genomics Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry Place of Nanofiltration for Assuring Viral Safety of Biologicals
Current Nanoscience Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach
Current Pharmaceutical Design Relevance of the Neuropeptide Y System in the Biology of Cancer Progression
Current Topics in Medicinal Chemistry Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome
Current Alzheimer Research Bioactive Metabolites from Pathogenic and Endophytic Fungi of Forest Trees
Current Medicinal Chemistry Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics